- Tubelator AI
- >
- Videos
- >
- News & Politics
- >
- Moderna CEO on China Investment and Vaccine Updates for Growth Post-Pandemic
Moderna CEO on China Investment and Vaccine Updates for Growth Post-Pandemic
Learn about Moderna's plans to bounce back post-COVID, including advancements in vaccine pipeline and positive trial results, as well as a $1 billion investment in MRNA manufacturing in China to boost global presence.
Install Tubelator On Chrome
Video Summary & Chapters
No chapters for this video generated yet.
Video Transcript
Moderna looking to rebound from its COVID slump, the pharma company announcing advancements
in its Moderna and mRNA rather vaccine pipeline, along with unveiling positive phase 3 trial
results for its next generation COVID-19 vaccine.
Yahoo!
Finance Health reporter, Anjali Kemlani, is here with us.
Anjali, what did you learn in this interview?
Well, it's interesting because Moderna, we know as just the COVID-19 company, but it's
a potential growth, pulling the company back from that post-pandemic law that we saw last
year.
And that's why CEO Stefan Bensel announced these new initiatives, the new vaccine updates,
at their annual vaccines date to date.
The company is also looking to boost its global presence with a $1 billion investment in
MRN manufacturing in China.
We know that's an important area.
Large market cap firms plan, but recent efforts by Congress to ban Chinese biotech companies
has been creating a little bit of tension in the industry. It seems like this tension is not
spilling over for Ben-Sel. He told Yahoo Finance earlier today that he is not worried. Here's
what he has to say. I think there's a very strong agreement at the highest level between the U.S.
government and China government that they want to collaborate on healthcare, on the climate,
and on food insecurity. Those are the free topics where at the highest level they want to
collaborate. We want to help people and to protect people. That's what the company has been
set up for. We've all those vaccines in respiratory and in latent. We want as many people in the
world to be able to benefit from those products. So we prevent disease.
So potentially carve out there for the company. Meanwhile, Moderna is also focused on ramping up its
research and development. That's an area it has to be dedicated to to continue that growth.
It recently got a $750 million infusion
from Blackstone Life Sciences for its flu program.
And that's the initial thing that Mender and I had been working on
before they've heard it to COVID.
It's also advancing several candidates in its pipeline
that would boost off-season business
despite cutbacks on manufacturing last year.
One of its biggest partners there was Cattleint,
and they are now being acquired by Nuvo Nordis.
So I asked myself, that's gonna change anything
or affect the company. Here's what he said.
The purchase of catalanth by Novo and all this did not affect anything for us because actually we are moving out of catalanth,
the Indian site which is one considered there as part of planning for 24.
What is important is the latent virus are not produced during the season.
So if you think about Moderna, today, or manufacturing is not as efficient as it should be because we make COVID for the season.
But let's say in Q1, we don't make much product.
We make clinical trial lots for all the clinical trial studies,
but we don't make commercial product enough factory.
So all those latent virus as a launch,
we can make them in Q1 or Q2 ahead of a season
and have a much better utilization
and of cost of good will improve a lot as we launch those products.
So we don't need to add manufacturing,
we don't need to add CapEx,
so it's a great news in terms of all efficiencies
